

humans, does not substantially bind aggregated A β in the brain.

- 31
cont
102. The method of any one of claims 95-101, wherein the subject has or is at risk for Alzheimer's disease, or Down's syndrome.
103. The method of any one of claims 95-101, wherein the subject is not diagnosed with Alzheimer's disease, or Down's syndrome.
104. The method of any one of claims 95-103, wherein the antibody is administered by a peripheral route.
105. The method of claim 104, wherein the antibody is administered by an intravenous route.
106. A method of treating Alzheimer's disease, comprising administering to a patient in need thereof an effective amount of the antibody or fragment of any one of claims 68-86.

REMARKS

Set forth below is a table indicating support for newly added Claims 68-106. The page and line number indicated in the table correspond to the first line of the paragraph containing the supporting disclosure.

| CLAIM | SUPPORT |
|-------|--|
| 68 | Page 8, line 17; page 27, line 2; page 31, line 19 |
| 69 | Page 8, line 17 |

| | |
|-----|--|
| 70 | Page 8, line 17 |
| 71 | Page 15, line 22 |
| 72 | Page 20, line 27 |
| 73 | |
| 74 | |
| 75 | |
| 76 | |
| 77 | Page 57, line 29 |
| 78 | |
| 79 | Page 20, line 27; page 58, line 6 |
| 80 | Page 20, line 27; page 58, line 6 |
| 81 | Page 20, line 27; page 58, line 6 |
| 82 | Page 52, line 21 |
| 83 | Page 31, line 19 |
| 84 | Page 20, line 27; page 49, line 14; page 57, line 11 |
| 85 | Page 31, line 19 |
| 86 | Page 52, line 21 |
| 87 | |
| 88 | |
| 89 | |
| 90 | |
| 91 | |
| 92 | |
| 93 | |
| 94 | Page 22, line 4; page 31, line 19 |
| 95 | Page 1, line 27; page 57, line 11; page 17, line 14; page 18, line 6 |
| 96 | Page 21, line 11; page 22, line 33; page 23, line 8 |
| 97 | Page 1, line 27; page 57, line 11 |
| 98 | |
| 99 | |
| 100 | |
| 101 | |
| 102 | Page 4, line 10; page 4, line 25; page 9, line 18; page 10, line 30 |
| 103 | |
| 104 | Page 8, line 17 |
| 105 | Page 8, line 17 |
| 106 | |

New claims 68-106 of the present application are substantially copied from the claims of International Patent Application Publication No. WO 01/62801, published August 30, 2001 (U.S. Applicants: Holtzman, David M.; DeMattos,

Ronald; Bales, Kelly, R.; Paul, Steven; and, Tsurushita, Naoya) to preserve Applicant's rights under 35 U.S.C. § 135(b)(2). The claims copied in the instant application correspond to the claims of WO 01/62801 as shown in the following table.

| WO 01/62801 CLAIMS | NEW CLAIMS |
|--------------------|------------|
| 1 | 68 |
| 2 | 69-71 |
| 3 | 72 |
| 4 | 73 |
| 5 | 74 |
| 6 | 75 |
| 8 | 76 |
| 10 | 77 |
| 18 | 78 |
| 19 | 79 |
| 20 | 80 |
| 21 | 81 |
| 23 | 82 |
| 24 | 83 |
| 25 | 84 |
| 26 | 85 |
| 27 | 86 |
| 28 | 87 |
| 29 | 88 |
| 34 | 89 |
| 35 | 90 |
| 36 | 91 |
| 37 | 92 |
| 38 | 93 |

| | |
|----|-----|
| 39 | 94 |
| 40 | 95 |
| 41 | 96 |
| 42 | 97 |
| 43 | 98 |
| 44 | 99 |
| 45 | 100 |
| 46 | 101 |
| 47 | 102 |
| 48 | 103 |
| 49 | 104 |
| 50 | 105 |
| 64 | 106 |

WO 01/62801 claims benefit of the following U.S. Provisional Applications: 60/184,601 filed February 24, 2000; 60/254,465 filed December 8, 2000; and, 60/254,498 filed December 8, 2000. Copies of WO 01/62801, U.S. Provisional Applications 60/184,601, 60/254,465, and, 60/254,498 will be provided in an Information Disclosure Statement.

Summary

In light of the above amendment, consideration of the subject patent application is respectfully requested. Please charge any deficiency or overpayment to Deposit Account No. 06-0130.

Respectfully submitted,



Kevin M. Farrell
Attorney for Applicants
Registration No. 35,505
(207) 363-0558

York Harbor, ME 03911

Date: 8/30/02